Text Size

Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study

Ansari E., Pavicic-Astalos J., Ayan F., King A.J., Kinsella M., Ng E., Nita A., The VISIONARY Group

  • 2021
  • Advances in Therapy
View publication
  • Therapeutic Area


  • Categories

    Clinical development

  • Affiliations

    Ansari, E., Maidstone and Tunbridge Wells NHS Trust, University of Kent at Canterbury, Kent, United Kingdom; Pavicic-Astalos, J., Institute of Eye Surgery, UPMC Whitfield, Waterford, Ireland; Ayan, F., Santen UK Ltd, St Albans, United Kingdom; King, A.J., Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Kinsella, M., Buckinghamshire Healthcare NHS Trust, Stoke Mandeville Hospital, Aylesbury, Buckinghamshire, United Kingdom; Ng, E., Institute of Eye Surgery, UPMC Whitfield, Waterford, Ireland; Nita, A., Royal Victoria Infirmary, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; The VISIONARY Group

Related Publications

Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.

Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.

The Development of a SIBS Shunt to Treat Glaucoma

Pinchuk L.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022